Sacituzumab Govitecan Plus Pembrolizumab Elicits Antitumor Activity in NSCLC
Sandip P. Patel, MD, discusses the exploration of sacituzumab govitecan in the EVOKE-01 and EVOKE-02 trials in NSCLC and expands on future treatment directions with the agent in this patient population.
San Diego United States Sandipp Patel University Of California Moores Cancer Center International Association
Source: onclive.com